Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company, announced it will host a virtual key opinion leader $(KOL)$ event on June 16, 2025, to discuss the positive results from a Phase 3 clinical trial of denifanstat, a novel treatment for moderate to severe acne vulgaris. The trial, conducted in China by Ascletis, Sagimet's license partner, demonstrated that denifanstat, a once-daily oral fatty acid synthase (FASN) inhibitor, met all primary and secondary endpoints versus placebo and was generally well tolerated. The event will feature insights from Neal Bhatia, MD, and include a live Q&A session. Additionally, Sagimet will discuss its newly initiated Phase 1 study for its second FASN inhibitor drug candidate, TVB-3567, intended for acne treatment in the U.S. A replay of the event will be available on Sagimet's website for 90 days post-event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.